The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 8 of the 18 sources its claims cite were checked for support.
Teclistamab in Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better). RESULTS: Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2). CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
39 Own result · 14 Own interpretation · 9 Own method · 6 No full text of the sources · 2 Supported · 2 Supported so far · 2 Partly supported · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [6] source
Table 2 reports grade 3 or higher cytokine release syndrome in 7 of 128 patients and grade 3 neurotoxic effects in 4 of 128 after ide-cel infusion. The Methods identify the treated population as patients with relapsed and refractory multiple myeloma. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [8] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines).”
- Also stated in: § PATIENTS · plain
“Before study entry, 148 patients (89.7%) had resistance to the previous line of therapy, 128 (77.6%) had triple-class refractory disease, and 50 (30.3%) had penta-drug refractory disease.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Responses occurred in 104 of 165 patients (63.0%; 95% confidence interval [CI], 55.2 to 70.4).”
- Also stated in: § RESULTS · plain
“the overall response rate was 63.0%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1)”
- Also stated in: § RESULTS · plain
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan–Meier estimate of maintenance of response for at least 12 months was 68.5% (95% CI, 57.7 to 77.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Otherwise, response rates were consistent across most clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities and those with penta-drug refractory disease (Fig. S2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hypogammaglobulinemia occurred in 123 patients (74.5%) as determined by means of adverse-event reporting, laboratory analyses (IgG level, <500 mg per deciliter), or both”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 123- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 65 patients who had a complete response or better, 30 (46%) had no minimal residual disease (Table S4).”
- Also stated in: § RESULTS · plain
“the MRD-negativity rate among the patients with a complete response or better was 46%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plainn = 65- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease (at a threshold of 10−5) was reported in 44 patients (26.7%; 95% CI, 20.1 to 34.1).”
- Also stated in: § RESULTS · plain
“A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plainn = 44- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a complete response or better occurred in 65 (39.4%)”
- Also stated in: § RESULTS · plain
“65 patients (39.4%) having a complete response or better”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plainn = 65- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS · plain
- It may state two separate claims as one. 31
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Patients section (page not available) reports that 12 of 140 enrolled patients discontinued before ide-cel infusion, an attrition rate of about 8.6%, and that some patients received bridging therapy during manufacturing. It does not establish a minimum four-week production period, a requirement for access to specialized care centers, or that waiting caused the discontinuations. (LLM, conf=0.85)
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Discussion and future perspectives section (page unavailable) says CAR T-cell treatment involves a specialized center and that manufacturing takes several days to weeks, during which disease may progress. It does not establish a minimum four-week production period or an attrition rate of approximately 10–15%. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Such absence of minimal residual disease has been associated with improved overall survival and progression-free survival in patients with myeloma.14-16”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [14] source
- Supportedcites [15] source
The Introduction states that MRD-negative status is associated with improved progression-free survival (PFS) and overall survival (OS). The Discussion likewise reports prior multiple-myeloma findings for both outcomes; the paper's own OS data were immature, but the claim does not attribute an OS result to this study's analysis. (LLM, conf=0.94)
- Supportedcites [16] source
The Discussion states that MRD negativity is associated with improved survival in both newly diagnosed and relapsed/refractory myeloma. The Introduction links MRD negativity with prolonged progression-free and overall survival, supporting both endpoints in the claim. (LLM, conf=0.90)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03), except for cytokine release syndrome (Table S2) and immune effector cell–associated neurotoxicity syndrome, which were graded according to the criteria of the American Society for Transplantation and Cellular Therapy.12”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Supportedcites [12] source
The citation supports the exception for CRS and ICANS: the paper sets out consensus grading criteria for both in its ‘Consensus on CRS Grading (Table 2)’ and ‘Consensus on ICANS Grading for Adults’ sections (page not available). The citing study’s choice to grade its other adverse events using CTCAE v4.03 is not attributed to this source. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point of the phase 2 study was the overall response rate, which was defined as a partial response or better according to the criteria of the International Myeloma Working Group, as assessed by an independent review committee”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Response criteria section recommends IMWG criteria for clinical trials and endorses the IMWG definition of partial response; the Minimal response section also distinguishes partial response or better from minimal response. The paper does not establish that overall response rate was the primary endpoint of the particular phase 2 study or that an independent review committee assessed it (pages not provided). (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [11] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of the 19 deaths due to adverse events in our study, 12 were attributed to Covid-19, which was consistent with the higher mortality observed from Covid-19 in patients with hematologic cancers during this time frame.24”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [24] source
The citation supports the background comparison, not the citing authors’ own count of 12 COVID-19 deaths among 19 adverse-event deaths. The Discussion reports high COVID-19 mortality in patients with hematologic malignancies and says it was substantially higher than in the general population, while cautioning that the estimate may be elevated by the large proportion of hospitalized patients. (LLM, conf=0.92)
plaincorrelationaln = 19- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“median, five previous therapy lines”
- Also stated in: § PATIENTS · plain
“Patients had received a median of 5 previous lines of therapy (range, 2 to 14)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Teclistamab exposure was sustained over the predetermined target level (6 μg per milliliter, based on the upper boundary of an experimentally determined range of the 90% maximal effective concentration) with a low peak-to-trough ratio (Fig. S3).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome occurred in 119 patients (72.1%). Most events occurred after step-up and cycle 1 doses, with 6 patients (3.6%) having cytokine release syndrome in cycle 2 or later. Most events of cytokine release syndrome were grade 1 or 2 in severity and fully resolved, except for one grade 3 event”
- Also stated in: § RESULTS · plain
“cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 119- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were lower in patients with extramedullary disease, stage III disease, and at least 60% marrow replacement by plasma cells and were higher in those who had received no more than three previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“thrombocytopenia (in 66 [40.0%])”
- Also stated in: § RESULTS · plain
“thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 66- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 68 patients (41.2%) died, with most deaths (41) attributed to progressive disease (Table S9). Nineteen patients died from adverse events, including 12 deaths from coronavirus disease 2019 (Covid-19). Five deaths were considered by investigators to be related to teclistamab”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plaindirectn = 68- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, reductions in soluble BCMA levels occurred during the first 4 cycles of treatment in 63 of 72 evaluable patients (88%) who had a partial response or better, whereas all the evaluable patients who did not have a response (9 of 9 patients) had increased levels of soluble BCMA.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
plaincorrelationaln = 72- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 98 patients (59.4%) received at least 6 months of teclistamab treatment, and 79 patients (47.9%) received at least 9 months of treatment.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
plainn = 98- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 165 patients reported having an adverse event (Table 2 and Table S5), which were grade 3 or 4 in 156 patients (94.5%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients had a total of 9 events of immune effector cell–associated neurotoxicity syndrome, all either grade 1 or 2. Of these 9 events, 7 were concurrent with cytokine release syndrome, and all 9 events resolved without discontinuation or dose reduction.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plaincorrelationaln = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“neutropenia (in 117 patients [70.9%])”
- Also stated in: § RESULTS · plain
“neutropenia (in 70.9%; grade 3 or 4, 64.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 117- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Injection-site reactions were reported in 60 patients (36.4%); all such events were grade 1 or 2.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 60- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the onset of cytokine release syndrome was 2 days (range, 1 to 6) after the most recent dose, and the median duration was 2 days (range, 1 to 9).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigator-assessed neurotoxic events, including immune effector cell–associated neurotoxicity syndrome, were reported in 24 patients (14.5%).”
- Also stated in: § RESULTS · plain
“Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell–associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 24- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“anemia (in 86 [52.1%])”
- Also stated in: § RESULTS · plain
“anemia (in 52.1%; grade 3 or 4, 37.0%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 86- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the first response was 1.2 months (range, 0.2 to 5.5), and the median time until a best response was 3.8 months (range, 1.1 to 16.8).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One patient had a dose reduction during cycle 21 because of recurrent neutropenia, and 104 patients (63.0%) skipped a dose because of adverse events. Two patients discontinued teclistamab because of adverse events (grade 3 adenoviral pneumonia and grade 4 progressive multifocal leukoencephalopathy).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plaindirectn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As of March 16, 2022, 70 patients (42.4%) were continuing to receive treatment (Fig. S1), with a median treatment duration of 8.5 months (range, 0.2 to 24.4).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
plainn = 70- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 126 patients (76.4%); 74 patients (44.8%) had grade 3 or 4 infections.”
- Also stated in: § RESULTS · plain
“Infections were frequent (in 76.4%; grade 3 or 4, 44.8%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
plainn = 126- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The overall depth of response was highlighted by the observation that 26.7% of the patients were found to have no minimal residual disease at a sensitivity level of 10−5; these patients made up 82% of those in whom minimal residual disease could be evaluated.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2.”
- Also stated in: § DISCUSSION · plain
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > CONCLUSIONS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § DISCUSSION · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sponsor established a safety evaluation team to monitor patient safety throughout the phase 1 study. In phase 2, safety was monitored through continuous review by the sponsor.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, subgroup analyses suggest that patients who have received no more than three previous therapy lines may have a better response rate than those who have received more than three therapies, a finding that supports the use of teclistamab in earlier therapy lines (although the confidence intervals for this finding are wide).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Teclistamab redirects CD3+ T cells to BCMA+ myeloma cells, resulting in T-cell activation and subsequent lysis and death of BCMA+ cells.18”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [18] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median relative dose intensity was high, and dose reductions and discontinuations owing to adverse events were infrequent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The safety and efficacy populations for this analysis included all the patients who had received at least one dose of teclistamab at the recommended phase 2 dose in phase 1 or phase 2 as of September 7, 2021.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were also compared across various prespecified subgroups, including those defined according to cytogenetic risk, refractory status, and number of previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For phase 2, we determined that a sample size of 100 patients would provide a power of at least 85% to establish an overall response rate of more than 30% at a one-sided significance level of 0.025, assuming an overall response rate of at least 45%.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
hedgedn = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Adverse events in this phase 1–2 trial were common and included low-grade cytokine release syndrome and grade 3 or 4 cytopenia and infection in a patient population that has an increased susceptibility to infection due to the immunodeficiency associated with myeloma and immunosuppressive effects of previous myeloma therapies.23”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [23] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease was assessed by next-generation sequencing of DNA obtained from bone marrow aspirate (clonoSEQ assay, version 2.0 [Adaptive Biotechnologies]) with a threshold of 10−5 cells.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each study site. All the patients provided written informed consent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the authors affirm that the trial was conducted in accordance with the study protocol and vouch for the accuracy and completeness of the data.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Teclistamab is readily available.
“Teclistamab is readily available and has been associated with rapid onset of response after a median of approximately 1 month of treatment.”
The paper relies on this without support.
No CD3-redirecting therapy has been approved for the treatment of myeloma.
“Although clinical proof of concept has been obtained for other CD3-redirection platforms in other indications,19-21 no CD3-redirecting therapy has been approved for the treatment of myeloma.”
The paper relies on this without support.
Cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations.
“Although cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations, the response rates observed with teclistamab (63%) compare favorably with those of belantamab mafodotin”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Two BCMA-targeting bispecific antibodies, teclistamab and elranatamab, have been approved for use in patients with relapsed myeloma who have received at least 4 prior regimens.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and favorable to the BCMA-targeting antibody–drug conjugate, belantamab mafodotin (ORR 32%, median DOR 11.0 months and median PFS 2.8 months) after a median follow-up of 12.4 months4,9,19,23.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab and elranatamab are bispecific antibodies produce an immunotherapeutic effect by binding to BCMA on myeloma cells on one arm and CD3 on T cells with the other.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
The cited source says what the claim attributes to it.
In the citing paper
“The primary endpoint in phase 2 was overall response rate per IMWG criteria,11 based on independent committee review, which was defined as the proportion of patients who had a partial response or better.”
From Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab, a bispecific antibody targeting CD3×BCMA,6 demonstrated deep and durable responses in heavily pretreated RRMM in the phase 1/2 MajesTEC-1 study.7,8”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“In this trial, 165 RRMM patients were treated with Teclistamab, and the following key outcomes were observed 63.0% ORR, 58.8% VGPR, and 39.4% CR. These results demonstrate the significant clinical activity of Teclistamab in RRMM patients who have received multiple prior lines of therapy. The high ORR, VGPR rate, and CR rate indicate substantial anti-myeloma activity of Teclistamab. Additionally, t”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [209]
The cited source says what the claim attributes to it.
In the citing paper
“The lower response rate observed in patients with extramedullary disease reflects the historically poor prognosis in this subgroup and has also been observed with other anti-BCMA-targeted agents such as belantamab mafodotin and teclistamab4,19.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationVijenthira, A., Gong, I. Y., Fox, T. A., Booth, S., Cook, G., Fattizzo, B., Martín-Moro, F., Razanamahery, J., Riches, J. C., Zwicker, J., et al. (2020) · Blood · doi:10.1182/blood.2020008824 · Cited by 625
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
Self-citationBispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.93 · Cited by 478
Cited by
Sorted by citations
Items 101–200 of 1,251
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Nath, K., Shekarkhand, T., Nemirovsky, D., Derkach, A., Costa, B., Nishimura, N., Farzana, T., Rueda, C., Chung, D., Landau, H., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01043-5 · Cited by 31
Self-citationCarretero-Iglesia, L., Hall, O. J., Berret, J., Pais, D., Estoppey, C., Chimen, M., Monney, T., Loyau, J., Dreyfus, C., Macoin, J., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00821-1 · Cited by 56
“Roughly 26.7% of patients treated with teclistamab were found MRD negative 5 .”
InfluentialSelf-citationEnriching single-arm clinical trials with external controls: possibilities and pitfalls
Lambert, J., Lengliné, É., Porcher, R., Thiébaut, R., Zohar, S., & Chevret, S. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022009167 · Cited by 55
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
Kumar, S. K., Mateos, M., Ye, J. C., Atrash, S., Magen, H., Quach, H., Chu, M. P., Trudel, S., Richter, J. R., Rodríguez‐Otero, P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2514752 · Cited by 51
Self-citationA phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E-mutated multiple myeloma
Giesen, N., Chatterjee, M., Scheid, C., Poos, A. M., Besemer, B., Miah, K., Benner, A., Becker, N., Moehler, T., Metzler, I., et al. (2023) · Blood · doi:10.1182/blood.2022017789 · Cited by 48
Self-citationMiao, X., Wu, L. S., Lin, S. X. W., Xu, Y. C., Chen, Y., Iwaki, Y., Kobos, R., Stephenson, T., Kemmerer, K., Uhlar, C., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00989-z · Cited by 48
“within the first month of treatment, and a greater reduction in sBCMA tended to occur in patients with deeper responses to teclistamab at the RP2D and in phase I dosing [15, 16].”
BackgroundMethodInfluentialSelf-citationImmunotherapy for the treatment of multiple myeloma
Boussi, L. S., Avigan, Z. M., & Rosenblatt, J. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1027385 · Cited by 48
“6% grade ≥3) and 15% neurotoxicity (0 grade 3) (113).”
Bisht, K. K., Fukao, T., Chiron, M., Richardson, P. G. G., Atanackovic, D., Chini, E. N., Chng, W. J., de Velde, H. J. V., & Malavasi, F. (2023) · Cancer Medicine · doi:10.1002/cam4.6619 · Cited by 50
Jelı́nek, T., Žihala, D., Sevcikova, T., Sithara, A. A., Kapustová, V., Sahinbegovic, H., Venglár, O., Muroňová, L., Broskevičová, L., Nenarokov, S., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02206-w · Cited by 50
Anderson, L. D., Dhakal, B., Jain, T., Oluwole, O. O., Shah, G. L., Sidana, S., Perales, M., & Pasquini, M. C. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.022 · Cited by 48
Self-citationShi, Q., Paiva, B., Pederson, L., Dimier, N., Talpes, E., Prior, T. J., Órfão, A., Moreau, P., Sonneveld, P., Kumar, S. K., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02020 · Cited by 44
Self-citationMouhieddine, T. H., Oekelen, O. V., Melnekoff, D. T., Li, J., Ghodke‐Puranik, Y., Lancman, G., Thibaud, S., Pan, D., Rajeeve, S., Agte, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007923 · Cited by 44
“Number of prior lines of therapy, median (min-max) 6 (3-17) 7 (3-16) 6 (3-17) .”
InfluentialSelf-citationBispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
Swan, D., Murphy, P. T., Glavey, S. V., & Quinn, J. (2023) · Cancers · doi:10.3390/cancers15061819 · Cited by 42
“CRS occurred in 72%, immune effector cell-associated neurotoxicity syndrome (ICANS) in 3%, and infections in 76%, of which 45% were grade 3–4 events [27].”
BackgroundCheng, L., Chen, L., Shi, Y., Gu, W., Ding, W., Zheng, X. W., Liu, Y., Jiang, J., & Zheng, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01956-6 · Cited by 49
“Compared to other BCMA/CD3 BSABs, teclistamab has demonstrated higher efficacy and longer survival (ORR, 63%; CR, 39.4%; mOS, 18.3 months) [67] in triple-refractory patients and has therefore been approved for marketing by the FDA.”
BackgroundInfluentialSaegusa, K., Tsuchida, Y., Komai, T., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030929 · Cited by 42
“Teclistamab, which targets CD3 and BCMA and is used in relapsed or refractory multiple myeloma [70], has demonstrated promise in treating refractory autoimmune diseases, including systemic sclerosis, Sjögren’s syndrome, and rheumatoid arthritis (RA) [68].”
Bispecific antibodies: unleashing a new era in oncology treatment
Shui, L., Wu, D., Yang, K., Sun, C., Li, Q., & Yin, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02390-y · Cited by 51
“The treatment was well tolerated, with hematological toxicity and CRS (mostly grade 1 or 2) being the most common TRAEs [54].”
Connolly, K., Brungs, D., Szeto, E., & Epstein, R. J. (2013) · Current Oncology · doi:10.3747/co.21.1661 · Cited by 42
Bangolo, A., Amoozgar, B., Mansour, C., Zhang, L., Gill, S. K., Ip, A., & Cho, C. (2025) · Cancers · doi:10.3390/cancers17020282 · Cited by 50
Tan, C. R. C., Asoori, S., Huang, C., Brunaldi, L. A. M., Popat, R., Kastritis, E., Martínez‐López, J., Bansal, R., Corraes, A. D. M. S., Chhabra, S., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01259-z · Cited by 55
Self-citationCAR T-cell therapy in multiple myeloma: mission accomplished?
Rasche, L., Hudecek, M., & Einsele, H. (2023) · Blood · doi:10.1182/blood.2023021221 · Cited by 44
Trudel, S., McCurdy, A. B. R., Louzada, M., Parkin, S., White, D. J., Chu, M. P., Kotb, R. R., Mian, H. S., Othman, I., Su, J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02703-y · Cited by 41
Mohan, M., Szabó, A., Cheruvalath, H., Clennon, A., Bhatlapenumarthi, V., Patwari, A., Balev, M., Bhutani, D., Shrestha, A., Thanendrarajan, S., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01282-0 · Cited by 47
“B-cell maturation antigen (BCMA) targeting bispeci fi c antibodies (bsAb) for multiple myeloma (MM) have shown unprecedented clinical ef fi cacy in patients with relapsed refractory disease [1 – 4].”
Jiménez‐Segura, R., Rosiñol, L., Cibeira, M. T., de Larrea, C. F., Tovar, N., Rodríguez‐Lobato, L. G., Bladé, E., Moreno, D. F., Oliver‐Caldés, A., & Bladé, J. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00730-5 · Cited by 42
“teclistamab had plasmacytomas and a lower response rate was observed in this population [36].”
BackgroundSelf-citationNew Biological Therapies for Multiple Myeloma
Garfall, A. L. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-033815 · Cited by 47
Self-citationCardiovascular toxicities associated with bispecific T-cell engager therapy
Sayed, A., Munir, M., Ghazi, S. M., Ferdousi, M., Krishan, S., Shaaban, A., Habib, A., Kola-Kehinde, O. O., Ruz, P., Khan, S. N., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008518 · Cited by 41
Banerjee, R. K., Mohan, M., Rejeski, K., Puliafito, B. R., Cirstea, D. D., Kaur, G., Midha, S., McCaughan, G. J. B., Kumar, N. M., Mehra, N., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016490 · Cited by 40
Molecular and immunological mechanisms of clonal evolution in multiple myeloma
Forster, S., Radpour, R., & Ochsenbein, A. F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1243997 · Cited by 44
Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
Chakraborty, R., Bhutani, D., Maurer, M. S., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00950-3 · Cited by 36
“To the editor: Bispeci fi c antibodies (bsAbs) targeting B-cell maturation antigen (BCMA) have transformed the landscape of relapsed/refractory (R/ R) multiple myeloma, with single-agent response rates of 60 – 70% in patients who have undergone extensive prior treatments [1 – 3].”
BackgroundEngelhardt, M. M., Kortüm, K. M., Goldschmidt, H., & Merz, M. (2024) · Haematologica · doi:10.3324/haematol.2023.283058 · Cited by 50
“61,62 Ongoing trials are now investigating bispecific antibodies in combination with established anti-myeloma drugs in earlier lines of treat-Figure ment.”
Neri, P., Leblay, N., Lee, H., Gullà, A., Bahlis, N. J., & Anderson, K. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00913-y · Cited by 38
“%) and a median PFS of 12.5 months 54,55 (Table 1).”
InfluentialSelf-citationT-Cell Engagers—The Structure and Functional Principle and Application in Hematological Malignancies
Cech, P., Skórka, K., Dziki, L., & Giannopoulos, K. (2024) · Cancers · doi:10.3390/cancers16081580 · Cited by 42
“[97].”
Martin, J. M., Cheng, Q., Laurent, S. A., Thaler, F., Beenken, A. E., Meinl, E., Krönke, G., Hiepe, F., & Alexander, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910845 · Cited by 38
“In addition, we recently utilized the CD3-BCMA bispecific antibody teclistamab, approved for multiple myeloma [9], in a refractory case of SLE, which resulted in a complete clinical and serologic remission despite the discontinuation of immunosuppressive therapies.”
MethodLiang, X.-J., Wang, Y.-F., Luo, B.-W., Lin, B., Lu, W.-X., Tian, S., Liu, D., & Wang, L. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010064 · Cited by 38
T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
van de Donk, N. W. C. J., O’Neill, C. A., de Ruijter, M. E. M., Verkleij, C. P. M., & Zweegman, S. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000983 · Cited by 32
Self-citationFirestone, R., Lesokhin, A. M., & Usmani, S. Z. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0176 · Cited by 33
Self-citationTeclistamab: Mechanism of action, clinical, and translational science
Guo, Y., Cardé, N. A. Q., Kang, L., Verona, R. I., Banerjee, A., Kobos, R., Chastain, K. M., Uhlar, C., Pillarisetti, K., Doyle, M., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.13717 · Cited by 33
Self-citationDíez-Alonso, L., Falgàs, A., Arroyo-Ródenas, J., Romencín, P. A., Martínez, A., Gómez-Rosel, M., Blanco, B., Jiménez-Reinoso, A., Mayado, A., Pérez-Pons, A., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg7962 · Cited by 31
“Moreover, the FDA recently approved the BCMA-specific TCEs teclistamab ( 17 ) and elranatamab ( 18 ).”
BackgroundSelf-citationKorst, C. L. B. M., Groen, K., Bosman, P. W. C., van der Valk, F. M., Verkleij, C. P. M., Kruyswijk, S., de Ruijter, M. E. M., Heijink, D. M., Kuipers, M. T., Zweegman, S., et al. (2024) · HemaSphere · doi:10.1002/hem3.132 · Cited by 35
Self-citationExtramedullary Multiple Myeloma: Challenges and Opportunities
Ho, M., Paruzzo, L., Minehart, J. C., Nabar, N. R., Noll, J. H., Luo, T., Garfall, A. L., & Zanwar, S. (2025) · Current Oncology · doi:10.3390/curroncol32030182 · Cited by 39
Self-citationInnovative strategies for T cell engagers for cancer immunotherapy
Bergamaschi, C., Gaspar, M., Ciucci, T., Sitnikova, S. I., Cayatte, C., Pica, M., & Dovedi, S. J. (2025) · mAbs · doi:10.1080/19420862.2025.2531223 · Cited by 39
“100 While teclistamab and ABBV-383 have shown promising results in clinical trials, 35,39 dual-targeting approaches like ISB 2001 may offer advantages by increasing avidity to MM clones, with the goal to reduce sink effect by soluble BCMA and reduced toxicity from targeting the broadly expressed…”
Gagelmann, N., Ayuk, F. A., Klyuchnikov, E., Wolschke, C., Berger, S. C., & Kröger, N. M. (2023) · Haematologica · doi:10.3324/haematol.2022.282510 · Cited by 32
“15 Thus, together with results presented in our evidence synthesis, studies should evaluate the preferred treatment sequence or even a combination approach of bispeci fi c antibody and CAR T cells for patients with high-risk cytogenetics and for those with extrame-dullary disease.”
Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Hájek, R., Kim, K., Grosicki, S., Sia, H., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00330-4 · Cited by 35
Self-citationNovellis, D. D., Fontana, R., Giudice, V., Serio, B., & Selleri, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010645 · Cited by 34
“Drug-related toxicity includes infections, neutropenia, anemia, thrombocytopenia, grade I/II cytokine release syndrome, and neurological events [98,99].”
BackgroundImpacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
Binder, A. F., Walker, C. J., Mark, T. M., & Baljević, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1275329 · Cited by 33
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances
Guidi, L., Etessami, J. D., Valenza, C., Valdivia, A., Meric‐Bernstam, F., Felip, E., & Curigliano, G. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473148 · Cited by 38
Targeted immunotherapy: harnessing the immune system to battle multiple myeloma
Xu, L., Wen, C., Xia, J., Zhang, H., Liang, Y., & Xu, X. G. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01818-6 · Cited by 32
“Based on these fi ndings, an international, open-label phase 2 expansion study of teclistamab in patients with R/RMM is underway (NCT04557098) [122].”
BackgroundNew horizons in our understanding of precursor multiple myeloma and early interception
dos Santos, D. M. C., Toenges, R., Bertamini, L., Alberge, J.-B., & Ghobrial, I. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00755-x · Cited by 34
Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma
Cliff, E. R. S., Reynolds, G. K., Popat, R., Teh, B. W., Kesselheim, A. S., & Mohyuddin, G. R. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02197 · Cited by 30
Self-citationMoreau, P., van de Donk, N. W. C. J., Delforge, M., Einsele, H., Stefano, V. D., Perrot, A., Besemer, B., Pawlyn, C., Karlin, L., Manier, S., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02480-7 · Cited by 31
“5 mg/kg was well tolerated, with an overall response rate of 63% [15].”
BackgroundSelf-citationde Assis, L. H., Fassi, D. E., & Hutchings, M. (2023) · Hematology · doi:10.1182/hematology.2023000508 · Cited by 33
Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
McCurdy, A. B. R., Seow, H. Y., Pond, G. R., Gayowsky, A., Chakraborty, R., Visram, A., Kaedbey, R., D’Souza, A., Mohyuddin, G. R., Wildes, T. M., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.282905 · Cited by 30
Talquetamab in multiple myeloma
Liu, L., & Krishnan, A. Y. (2023) · Haematologica · doi:10.3324/haematol.2023.283931 · Cited by 29
Self-citationDima, D., Rashid, A., Davis, J. A., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19302 · Cited by 29
Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases
Düsing, C., Györfi, A., Stütz, A. N., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04238-4 · Cited by 29
“Four out of five patients treated with blinatumomab maintained normal levels of immunoglobulins, the immunoglobulin levels dropped below 400 mg dl −1 in all patients treated with teclistamab during longer follow-up 34,35 .”
Teclistamab in Relapsed or Refractory Multiple Myeloma
Pianko, M. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2211969 · Cited by 29
Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives
Liu, L., & Chen, J. (2022) · Medical Review · doi:10.1515/mr-2022-0033 · Cited by 28
“Most recently, the EMA has approved CD20xCD3 bispecific antibody (mosunetuzumab) for patients with relapsed or refractory disease of follicular lymphoma and BCMAxCD3 bispecific antibody (teclistamab) for patients with relapsed and refractory multiple myeloma [127, 128].”
BackgroundAnti-BCMA novel therapies for multiple myeloma
Sammartano, V., Franceschini, M., Fredducci, S., Caroni, F., Ciofini, S., Pacelli, P., Bocchia, M., & Gozzetti, A. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.138 · Cited by 32
Dima, D., Ullah, F., Mazzoni, S. A., Williams, L. S., Faiman, B. M., Kurkowski, A., Chaulagain, C. P., Raza, S., Samaras, C. J., Valent, J. N., et al. (2023) · Cancers · doi:10.3390/cancers15072160 · Cited by 32
Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma
Giralt, S. A., Jolles, S. R. A., Kerre, T. C. C., Lazarus, H. M., Mustafa, S. S., Papanicolaou, G. A., Ria, R., Vinh, D. C., & Wingard, J. R. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.05.008 · Cited by 30
“…and ciltacabtagene autoleucel), and bispecific T-cell engagers (eg, teclis-tamab); have improved survival and response rates in patients with MM. 47–51 These new therapies have a variety of mechanisms of actions to target MM, for example, proteasome inhibitors block proteasomes from clearing…”
BackgroundStandard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma
Sidana, S., Ahmed, N., Akhtar, O. S., Brazauskas, R., Oloyede, T., Bye, M., Hansen, D. K., Ferreri, C. J., Freeman, C. L. L., Afrough, A., et al. (2025) · Blood · doi:10.1182/blood.2024026216 · Cited by 32
Self-citationTedder, B., & Bhutani, M. (2025) · Cells · doi:10.3390/cells14141077 · Cited by 33
“In the MajesTEC-1 trial, Teclistamab demonstrated an ORR of 63% and median PFS of 11.3 months, whereas Elranatamab showed an ORR of 61% and median PFS of 15 months in the MagnetisMM-3 study [8,10].”
InfluentialAntibodies and bispecifics for multiple myeloma: effective effector therapy
Cipkar, C., Chen, C. I., & Trudel, S. (2022) · Hematology · doi:10.1182/hematology.2022000334 · Cited by 29
Current use of bispecific antibodies to treat multiple myeloma
Lee, H., Neri, P. E., & Bahlis, N. J. (2023) · Hematology · doi:10.1182/hematology.2023000433 · Cited by 29
Self-citationMohan, M., Szabó, A., Patwari, A., Esselmann, J., Patel, T., Bachu, R., Rein, L., Janardan, A., Bhatlapenumarthi, V., Annyapu, E., et al. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02233-2 · Cited by 31
Pan, D., & Richter, J. R. (2024) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-024-00740-z · Cited by 30
“To limit the severity of inflammatory toxicities, bispe - cific antibodies are initiated at subtherapeutic doses and are gradually “stepped up” to the treatment dose; it is following step-up doses or the first treatment dose that the vast major - ity of CRS events occur [6, 9, 10 ].”
InfluentialHow to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, F., Montes Gaisán, C., & de la Rubia Comos, J. (2022) · Cancers · doi:10.3390/cancers15010155 · Cited by 28
“Bi-specific drugs (BiABs) Teclistamab Conditional marketing authorisation for adult patients with RRMM, who have received at least three prior therapies [45,46]”
BackgroundMechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors
Weddell, J. C. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12928 · Cited by 27
Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma
Braun, A., Gouni, S., Pulles, A. E., Strati, P., Minnema, M. C., & Budde, L. E. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_433516 · Cited by 26
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions
Labanca, C., Martino, E. A., Vigna, E., Bruzzese, A., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., Morabito, F., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14353 · Cited by 33
“Teclistamab was the first BCMA-directed BsAb to receive approval (in October 2022), following the positive outcomes of the seminal MajesTEC-1 trial, which involved a similar RRMM population as those receiving CAR-T therapy [23, 24].”
InfluentialMechanistic insights into resistance mechanisms to T cell engagers
Cao, L., Leclercq-Cohen, G., Klein, C., Sorrentino, A., & Bacac, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1583044 · Cited by 31
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Elbezanti, W. O., Challagundla, K. B., Jonnalagadda, S. C., Budak-Alpdoǧan, T., & Pandey, M. K. (2023) · Pharmaceuticals · doi:10.3390/ph16030415 · Cited by 36
“Teclistamab-cqyv 2022 RRMM CRS, ICANS, fatigue, pneumonia, diarrhea, pyrexia, neutropenia, thrombocytopenia, and anemia MajesTEC-1 NCT0314518, NCT04557098 [140,141]”
BackgroundSoluble B-cell maturation antigen as a monitoring marker for multiple myeloma
Wiedemann, Á., Szita, V. R., Horváth, R., et al. (2023) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611171 · Cited by 26
“Recently it became a popular target for the development of cellular and noncellular immunotherapies in MM, several of which are now licensed for treatment, such as belantamab mafodotin (9), ciltacabtagene autoleucel (10), idecabtagene vicleucel (11), and teclistamab (12).”
BackgroundMultiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy
Rocchi, S., Zannetti, B. A., Marconi, G., & Lanza, F. (2024) · Cells · doi:10.3390/cells13100853 · Cited by 30
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Mohan, M., Oekelen, O. V., Akhtar, O. S., Cohen, A. D., & Parekh, S. S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432204 · Cited by 27
Liu, D., Hu, X., Chen, Z., Wei, W., & Wu, Y. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116441 · Cited by 31
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
Li, C., Zhou, K., Hu, Y., Zou, D., Chen, L., Chen, B., Liu, J., Zhang, X., Ren, H., Hu, K., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4879 · Cited by 30
Perrot, A., Hulin, C., Boumendil, A., Manjra, H., Leveque, A., Croizier, C., Dony, A., Mohty, M., Roussel, M., Manier, S., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.286118 · Cited by 25
Self-citationLutz, R., Poos, A. M., Solé-Boldo, L., John, L., Wagner, J., Prokoph, N., Baertsch, M. A., Vonficht, D., Palit, S., Brobeil, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adp6667 · Cited by 25
Frenking, J., Riedhammer, C., Teipel, R., Bassermann, F., Besemer, B., Bewarder, M., Braune, J., Brioli, A., Brunner, F., Dampmann, M., et al. (2025) · HemaSphere · doi:10.1002/hem3.70114 · Cited by 23
“6,9,11,27,28 Moreover, patients with prior BTCE exposure showed inferior response rates, PFS, and OS compared to all others, while no differences in DOR were observed.”
InfluentialSelf-citationLopatnikova, J., & Sennikov, S. V. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1679092 · Cited by 31
“Teclistamab (BCMA×CD3) became the fi rst bispeci fi c antibody approved for relapsed/refractory multiple myeloma, with an ORR of approximately 63% (61).”
Prevention of infections including vaccination strategies in multiple myeloma
Ludwig, H., & Kumar, S. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26766 · Cited by 29
“Noteworthily, 12 deaths of the 19 patients who died from adverse events were due to COVID-19.(122)”
BackgroundInfluentialImmunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
Abramson, H. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115674 · Cited by 23
“In addition, infections were noted in 76.4% of the patients [95].”
BackgroundInfluentialDas, S., Ailawadhi, S., Sher, T., et al. (2023) · Current Oncology · doi:10.3390/curroncol30110697 · Cited by 25
“Targeting BCMA via the use of cellular immunotherapies, such as chimeric antigen receptor (CAR) T cells or bi-specific antibodies has led to unprecedented response rates in patients with relapsed/refractory multiple myeloma [6–8].”
BackgroundOvercoming proteasome inhibitor resistance in the immunotherapy era
Patiño-Escobar, B., Talbot, A., & Wiita, A. P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.05.006 · Cited by 27
Hadidi, S. A., Heslop, H. E., Brenner, M. K., & Suzuki, M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.039 · Cited by 29
Targeting immunosenescence for improved tumor immunotherapy
Liu, Z., Zuo, L., Zhou, Z., Liu, S., Ba, Y., Zuo, A., Ren, Y., Zhang, C., Chen, Y., Ma, H., et al. (2024) · MedComm · doi:10.1002/mco2.777 · Cited by 24
“293 Currently, FDA has approved three BiTE molecules: blinatumomab and teclistamab, which target tumor-associated antigens via antibody-derived binding domains, and tebentafusp, which targets gp100 peptides in the MHC class I complex using a high-affinity TCR. 294,295”
MethodUllrich, F., Bröckelmann, P. J., Turki, A. T., Khan, A., Chiru, E.-D., Vetter, M. H. F., von Tresckow, B., Wirth, R., Córdoba, R., Ortiz‐Maldonado, V., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009462 · Cited by 25
The current socioeconomic and regulatory landscape of immune effector cell therapies
Sainatham, C., Yadav, D., Babu, A. D., Tallapalli, J. R., Kanagala, S. G., Filippov, E., Murillo-Chavez, F., Ahmed, N., & Lutfi, F. U. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1462307 · Cited by 30
van de Donk, N. V., Moreau, P., San-Miguel, J., Mateos, M.-V., Dimopoulos, M., Zweegman, S., Gay, F., Engelhardt, M., Mina, R., Zamagni, E., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00117-6 · Cited by 26
“Although patients with creative clearance less than 30–40 ml/min were excluded from clinical studies evaluating approved bispecific antibodies, 7,20,67 real-world evidence has shown that bispecific antibody treatment is feasible, without unexpected side-effects, in patients with severely impaired…”
Self-citationChari, A., van de Donk, N. W. C. J., Dholaria, B., Weisel, K. C., Mateos, M., Goldschmidt, H., Martin, T. G., Morillo, D., Reece, D. E., Rodríguez‐Otero, P., et al. (2025) · Blood · doi:10.1182/blood.2025029360 · Cited by 25
Self-citationBelantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
Morè, S., Offidani, M., Corvatta, L., Petrucci, M. T., & Fazio, F. (2023) · Cancers · doi:10.3390/cancers15112948 · Cited by 26
“Results from subcutaneous teclistamab, a T-cell redirecting bispecific antibody targeting BCMA, showed an impressive overall response rate (ORR) of 73% in heavily pretreated patients with a median of five prior lines of therapy [31].”
BackgroundTeclistamab in patients with multiple myeloma and impaired renal function
Joiner, L., Bal, S., Godby, K. N., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27063 · Cited by 24
“This observation is aligned with the lower likelihood of response to teclistamab in patients with EMD.(1) CRS occurrence and grading in these patients follows established data for teclistamab.”
BackgroundResultInfluentialSiegel, R. D., LeFebvre, K. B., Temin, S., Evers, A., Barbarotta, L., Bowman, R., Chan, A., Dougherty, D. W., Ganio, M. C., Hunter, B. D., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00216 · Cited by 24
“43 Other authors evaluated over 200 interventions conducted by pharmacists during counseling sessions, and half of these interventions involved herbal-product and drug interactions.”
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
McCue, A. C., Demarest, S. J., Froning, K., Hickey, M. J., Antonysamy, S., & Kuhlman, B. A. (2024) · mAbs · doi:10.1080/19420862.2024.2373325 · Cited by 23
Unlocking the potential of bispecific ADCs for targeted cancer therapy
Zeng, H., Ning, W., Liu, X., Luo, W., & Xia, N. (2024) · Frontiers of Medicine · doi:10.1007/s11684-024-1072-8 · Cited by 24
IgG replacement in multiple myeloma
Wonnaparhown, A., Hilal, T., Squire, J., Freeman, C., & Fonseca, R. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01107-6 · Cited by 23
“The cutoff for HG in various other studies has ranged from 500 – 700 mg/dL and has also been strati fi ed into mild (IgG 400 – 599 mg/dL), moderate (IgG 200 – 399 mg/dL), and severe (IgG 200 mg/dL) HG [6 – 8].”
BackgroundInfluentialvan de Donk, N. W. C. J., Rasche, L., Sidana, S., Zweegman, S., & Garfall, A. L. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0124 · Cited by 26
Self-citationArvanitis, P., Tziotis, A., Papadimatos, S., & Farmakiotis, D. (2025) · Current Oncology · doi:10.3390/curroncol32040198 · Cited by 22
Acute Kidney Injury in Cancer Immunotherapy Recipients
Joseph, A., Lafarge, A., Azoulay, É., & Zafrani, L. (2022) · Cells · doi:10.3390/cells11243991 · Cited by 23
“CD19 is currently the most widely used target (Blinatumomab), but bispecific antibodies redirecting T cells against CD20 (Mosunetuzumab) have recently been approved for follicular lymphoma and new antibodies targeting BCMA for multiple myeloma are likely to enter clinical practice in the near future [95].”
BackgroundCurrent Novel Targeted Therapeutic Strategies in Multiple Myeloma
Lin, C. (.-T., Tariq, M., Ullah, F., Sannareddy, A., Khalid, F., Abbas, H., Bader, A., Samaras, C., Valent, J., Khouri, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116192 · Cited by 25
“Three Three percent of patients developed grade 1 or 2 ICANS [36]. percent of patients developed grade 1 or 2 ICANS [36].”
Background
Metadata
- Authors
- Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, L., Mateos, M.-V., Bahlis, N., Popat, R., Besemer, B., Martínez-López, J., Sidana, S., Delforge, M., Pei, L., Trancucci, D., Verona, R., Girgis, S., Lin, S. X. W., Olyslager, Y., Jaffe, M., Uhlar, C., Stephenson, T., Van Rampelbergh, R., Banerjee, A., Goldberg, J. D., Kobos, R., Krishnan, A., & Usmani, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- From the Hematology Clinic, University Hospital Hôtel-Dieu, Nantes (P.M.), Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite (L.K.), and Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours (L.B.) — all in France; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.L.G.), and Janssen Research and Development, Spring House (R.V., S.G., S.X.W.L., C.U., T.S., A.B.) — both in Pennsylvania; the Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam (N.W.C.J.D.); Karolinska University Hospital at Huddinge, Stockholm (H.N.); Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Sanitaria de Navarra, Pamplona (J.F.S.-M.), Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Puj...
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-08-11
- Volume
- 387
- Issue
- 6
- Pages
- 495-505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10587778
- OpenAlex
- W4282033105
- Cited by
- 1,269
- References
- 25
- Citations by year
- 2026: 335 · 2025: 341 · 2024: 320 · 2023: 231 · 2022: 39
- FWCI
- 169.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Lirias (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- teclistamab, relapsed/refractory multiple myeloma, bispecific T-cell engagers, overall response rate, minimal residual disease negativity, progression-free survival, cytokine release syndrome, neurotoxicity, dose-limiting toxicity, subcutaneous administration, immunotherapy safety and efficacy
- MeSH terms
- Antineoplastic Agents, Immunological, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, CD3 Complex, Antibodies, Bispecific, B-Cell Maturation Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
